DK1653844T3 - Prionspecifikke peptidreagenser - Google Patents

Prionspecifikke peptidreagenser

Info

Publication number
DK1653844T3
DK1653844T3 DK04781105.4T DK04781105T DK1653844T3 DK 1653844 T3 DK1653844 T3 DK 1653844T3 DK 04781105 T DK04781105 T DK 04781105T DK 1653844 T3 DK1653844 T3 DK 1653844T3
Authority
DK
Denmark
Prior art keywords
prion
specific peptide
peptide reagents
reagents
specific
Prior art date
Application number
DK04781105.4T
Other languages
Danish (da)
English (en)
Inventor
Melissa D Michelitsch
Celine Hu
Roland N Zuckermann
Michael D Connolly
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1653844T3 publication Critical patent/DK1653844T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
DK04781105.4T 2003-08-13 2004-08-13 Prionspecifikke peptidreagenser DK1653844T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49496203P 2003-08-13 2003-08-13
US57036804P 2004-05-12 2004-05-12
US58650904P 2004-07-09 2004-07-09
PCT/US2004/026363 WO2005016127A2 (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents

Publications (1)

Publication Number Publication Date
DK1653844T3 true DK1653844T3 (da) 2013-03-11

Family

ID=34198970

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04781105.4T DK1653844T3 (da) 2003-08-13 2004-08-13 Prionspecifikke peptidreagenser

Country Status (13)

Country Link
US (1) US7439041B2 (OSRAM)
EP (1) EP1653844B1 (OSRAM)
JP (3) JP4709149B2 (OSRAM)
KR (1) KR101166012B1 (OSRAM)
AU (2) AU2004264953B2 (OSRAM)
BR (1) BRPI0413495A (OSRAM)
CA (1) CA2535261C (OSRAM)
DK (1) DK1653844T3 (OSRAM)
ES (1) ES2398394T3 (OSRAM)
IL (1) IL173480A0 (OSRAM)
MX (1) MXPA06001588A (OSRAM)
NZ (2) NZ580256A (OSRAM)
WO (1) WO2005016127A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US7691639B2 (en) * 2001-05-31 2010-04-06 Adlyfe, Inc. Misfolded protein sensor method
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
KR101166012B1 (ko) * 2003-08-13 2012-07-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 프리온-특이적 펩티드 시약
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
WO2006076497A2 (en) 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
CA2594840A1 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Elisa assays using prion-specific peptide reagents
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
AU2006254333B2 (en) * 2005-06-01 2011-02-17 Amgen Research (Munich) Gmbh Anti-IL2 antibodies
EP2383281A3 (en) * 2005-09-09 2012-01-04 Novartis AG Prion-specific peptoid reagents
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
JP2010523977A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンアッセイ
CA2684798A1 (en) * 2007-04-04 2008-10-16 Novartis Ag Prion elisa
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
US8709472B1 (en) * 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
EP2282753A1 (en) * 2008-04-30 2011-02-16 Novartis AG Assay for pathogenic conformers
EP2128618A1 (en) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. A process for monitoring the presence of pathogenic agents in biological fluids by nanostructured materials
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2012051498A2 (en) * 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
EP3370518B1 (en) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
WO2017196084A1 (ko) * 2016-05-10 2017-11-16 엘지전자 주식회사 이동 로봇 및 그 제어방법
WO2018005330A1 (en) * 2016-06-27 2018-01-04 Florida State University Research Foundation, Inc. Modified fragments from the octarepeat region of prion protein as hemin binders
WO2018053472A1 (en) * 2016-09-19 2018-03-22 University Of Houston System Compositions and methods of targeting cancer stem cells
JP2021004175A (ja) * 2017-09-04 2021-01-14 国立大学法人東北大学 コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246059A (en) 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
NZ318689A (en) * 1995-09-14 1999-02-25 Univ California Prion antibodies specific for native prpsc and use for detecting human prpsc in a source
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
ATE250767T1 (de) 1997-02-06 2003-10-15 Enfer Technology Ltd Immunoassay für spongiforme encephalopathien
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
ATE302269T1 (de) * 1998-04-14 2005-09-15 Sugen Inc Ste20-verwandte proteinkinasen
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
CA2361013A1 (en) 1999-01-25 2000-07-27 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
NZ516240A (en) 1999-06-23 2005-11-25 Caprion Pharmaceuticals Inc Prion protein peptides and uses thereof
WO2001007479A2 (en) 1999-07-27 2001-02-01 Imperial College Innovations Limited Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EP1216258A1 (en) * 1999-09-28 2002-06-26 Universität Zürich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
AU2001251358A1 (en) 2000-04-05 2001-10-23 V.I. Technologies, Inc. Prion-binding ligands and methods of using same
US6642171B2 (en) * 2000-04-28 2003-11-04 Synuthane International, Inc. Double metal cyanide catalysts containing polyglycol ether complexing agents
AU6887101A (en) 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
NZ523213A (en) 2000-07-07 2005-01-28 Applied Research Systems Early diagnosis of conformational diseases
GB0103508D0 (en) * 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
US7691639B2 (en) 2001-05-31 2010-04-06 Adlyfe, Inc. Misfolded protein sensor method
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
WO2003050139A2 (en) 2001-12-10 2003-06-19 Applied Research Systems Ars Holding N.V. Prion inhibiting peptides and derivatives thereof
EP1478931B2 (en) 2002-02-28 2018-11-07 Microsens Biophage Limited Binding of pathological forms of prion proteins
JP4421900B2 (ja) 2002-04-09 2010-02-24 ザ スクリップス リサーチ インスティテュート モチーフ・グラフトされたハイブリッドポリペプチドおよびその使用
US20040208919A1 (en) 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
EP1534746A2 (en) 2002-08-23 2005-06-01 Copenhagen Biotech Assets APS Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
ES2283608T3 (es) 2002-10-23 2007-11-01 Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A Secuencias peptidicas de union a la proteina prionica.
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
DK1953551T3 (da) 2002-12-03 2014-05-12 Univ North Carolina State Prion-proteinligander samt fremgangsmåder til anvendelse deraf
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
JP4783727B2 (ja) 2003-04-04 2011-09-28 パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレーテッド プリオンタンパク質結合物質と使用法
CA2522483A1 (en) 2003-04-14 2004-10-28 Julia T. Lathrop Method for identifying ligands specific for structural isoforms of proteins
KR101166012B1 (ko) * 2003-08-13 2012-07-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 프리온-특이적 펩티드 시약
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins

Also Published As

Publication number Publication date
MXPA06001588A (es) 2006-08-25
JP2013033060A (ja) 2013-02-14
JP4709149B2 (ja) 2011-06-22
AU2004264953B2 (en) 2009-07-23
EP1653844A2 (en) 2006-05-10
WO2005016127A3 (en) 2006-12-21
US20050118645A1 (en) 2005-06-02
NZ545385A (en) 2010-12-24
KR101166012B1 (ko) 2012-07-23
ES2398394T3 (es) 2013-03-15
EP1653844B1 (en) 2012-12-12
JP2007502120A (ja) 2007-02-08
US7439041B2 (en) 2008-10-21
AU2009225337B2 (en) 2012-12-06
NZ580256A (en) 2011-07-29
JP2010158247A (ja) 2010-07-22
CA2535261C (en) 2015-11-24
BRPI0413495A (pt) 2006-10-17
WO2005016127A2 (en) 2005-02-24
HK1090275A1 (en) 2006-12-22
KR20060066088A (ko) 2006-06-15
EP1653844A4 (en) 2009-01-14
CA2535261A1 (en) 2005-02-24
AU2004264953A1 (en) 2005-02-24
IL173480A0 (en) 2006-06-11
AU2009225337A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
DK1653844T3 (da) Prionspecifikke peptidreagenser
NO2014013I1 (no) Linaclotide
DE602004009744D1 (de) Reagenzbehälter
DE602004020635D1 (de) Lanzetten betreffende verbesserungen
NO20044347L (no) Anti-alfavbeta6-antistoff
ATE363383T1 (de) Schlingenware
FI20030402A0 (fi) Koaksiaaliresonaattorisuodatin
DE602004002567D1 (de) Piperidinbenzolsulfonamidderivate
ATE418924T1 (de) Marknagel
DE50311137D1 (de) Eriebauteile
NO20055459D0 (no) Prosesser
DK1752470T3 (da) GAG-bindende proteiner
DE602004016325D1 (de) Diosignalbandes
ATE462365T1 (de) Marknagel
ATE375761T1 (de) Marknagel
DE602004007839D1 (de) Tintebehalter
DE602004008426D1 (de) Airbagfaltverfahren
DE112004000620D2 (de) Struktoguss
DE10355350A8 (de) Elektromodul
DE602004016676D1 (de) Gasflüssigkeitsabscheider
DE50312763D1 (de) Schliessleiste
DE502004001629D1 (de) Bremsenprüfstand
DK1625148T3 (da) Peptidkompleks
DE50305802D1 (de) Stanz-prägeniet
DE502004008889D1 (de) Schaltgabel